Serum Bruton's tyrosine kinase and NF-κB in Hashimoto's thyroiditis ‒ a case-control study of potential diagnostic biomarkers
DOI:
https://doi.org/10.15584/ejcem.2026.2.17Keywords:
autoimmunity, biomarkers, Bruton's tyrosine kinase, Hashimoto's thyroiditis, hypothyroidism, NF-κBAbstract
Introduction and aim. Hashimoto's thyroiditis (HT) is the leading cause of hypothyroidism, yet its diagnosis relies on markers with known limitations. Bruton's tyrosine kinase (Btk) and nuclear factor kappa B (NF-κB) are implicated in B-cell-mediated autoimmunity. This study aimed to explore the serum levels and preliminary diagnostic potential of Btk and NF-κB in Iraqi patients with HT.
Material and methods. In this case-control study, 30 HT patients, 30 non-autoimmune hypothyroidism patients, and 60 healthy controls were enrolled from three centers in Karbala, Iraq. HT was defined by elevated TSH (>4.2 µIU/mL), reduced fT4 (<0.93 ng/dL), and positive anti-TPO and/or anti-Tg, whereas non-autoimmune hypothyroidism was defined by elevated TSH and low fT4 with negative thyroid autoantibodies. Serum Btk and NF-κB were measured by enzyme-linked immunosorbent assay. Thyroid hormones and autoantibodies were determined by electrochemiluminescence immunoassay. Receiver operating characteristic (ROC) analysis was performed to assess preliminary diagnostic accuracy for distinguishing HT from non-autoimmune hypothyroidism and healthy controls.
Results. Serum Btk and NF-κB levels were significantly elevated in HT patients compared to both control groups (Btk: 7.81±0.98 vs. 7.00±0.77 vs. 6.10±1.60 ng/mL; NF-κB: 1.90±0.71 vs. 0.91±0.21 vs. 0.84±0.39 ng/mL, p<0.001). In ROC analysis, NF-κB showed an area under the curve (AUC) of 0.95 (95% CI: 0.89–0.99) for discriminating HT from non-autoimmune hypothyroidism. Both biomarkers correlated positively with anti-TPO, anti-Tg, and TSH, and negatively with fT4.
Conclusion. Serum Btk and NF-κB were elevated in HT and showed preliminary associations with autoimmune activity. NF-κB, in particular, demonstrated promising initial diagnostic performance. These exploratory findings require validation in larger, independent cohorts.
Downloads
References
Vargas-Uricoechea H, Castellanos-Pinedo A, Urrego-Noguera K, Pinzón-Fernández MV, Meza-Cabrera IA, Vargas-Sierra H. A scoping review on the prevalence of Hashimoto's thyroiditis and the possible associated factors. Med Sci (Basel). 2025;13(2):43. doi:10.3390/medsci13020043
Kaur J, Jialal I. Hashimoto thyroiditis. StatPearls [Internet]. StatPearls Publishing; 2025.
Rydzewska M, Jaromin M, Pasierowska IE, Stożek K, Bossowski A. Role of the T and B lymphocytes in pathogenesis of autoimmune thyroid diseases. Thyroid Res. 2018;11(1):2. doi:10.1186/s13044-018-0046-9
Franco JS, Amaya-Amaya J, Anaya JM. Thyroid disease and autoimmune diseases. In: Anaya JM, Shoenfeld Y, Rojas-Villarraga A, eds. Autoimmunity: From Bench to Bedside. Bogota, Colombia: El Rosario University Press; 2013.
Ralli M, Angeletti D, Fiore M, et al. Hashimoto's thyroiditis: an update on pathogenic mechanisms, diagnostic protocols, therapeutic strategies, and potential malignant transformation. Autoimmun Rev. 2020;19(10):102649. doi:10.1016/j.autrev.2020.102649
Caturegli P, De Remigis A, Rose N. Hashimoto thyroiditis: clinical and diagnostic criteria. Autoimmun Rev. 2014;13(4-5):391-397. doi:10.1016/j.autrev.2014.01.007
Murad R, et al. The role of the neutrophil-to-lymphocyte ratio and the platelet-to-lymphocyte ratio in assessing hypothyroidism Hashimoto's thyroiditis. Ital J Med. 2025;19(2). doi:10.4081/itjm.2025.1953
Bilge M, Adas M, Yesilova A, Helvaci A. Platelet-to-lymphocyte ratio and its association with Hashimoto's thyroiditis. Diseases. 2023;11(1):15. doi:10.3390/diseases11010015
Aktas G, Sit M, Dikbas O, et al. Could red cell distribution width be a marker in Hashimoto's thyroiditis? Exp Clin Endocrinol Diabetes. 2014;122(10):572-574. doi:10.1055/s-0034-1383564
Aktas G, Duman TT, Atak BM, et al. Irritable bowel syndrome is associated with novel inflammatory markers derived from hemogram parameters. J Med Biochem. 2020;39(1):62-66.
Bilgin S, Aktas G, Zahid Kocak M, et al. Association between novel inflammatory markers derived from hemogram indices and metabolic parameters in type 2 diabetic men. Aging Male. 2020;23(5):923-927. doi:10.1080/13685538.2019.1632283
Aktas G, Yilmaz S, Kantarci DB, et al. Is serum uric acid-to-HDL cholesterol ratio elevation associated with Hashimoto's thyroiditis? Rom J Intern Med. 2021;59(4):403-408. doi:10.2478/rjim-2021-0023
Aktas G, Yildirim M, Akbulut A, et al. HALP and SII indexes in Hashimoto's thyroiditis. Postgrad Med. 2026. doi:10.1080/00325481.2026.2621575
Crofford LJ, Nyhoff LE, Sheehan JH, Kendall PL. The role of Bruton's tyrosine kinase in autoimmunity and implications for therapy. Expert Rev Clin Immunol. 2016;12(7):763-773. doi:10.1586/1744666X.2016.1152888
Mehra S, Nicholls M, Taylor J. The evolving role of Bruton's tyrosine kinase inhibitors in B cell lymphomas. Int J Mol Sci. 2024;25(14):7516. doi:10.3390/ijms25147516
Neys SF, Hendriks RW, Corneth OB. Targeting Bruton's tyrosine kinase in inflammatory and autoimmune pathologies. Front Cell Dev Biol. 2021;9:668131. doi:10.3389/fcell.2021.668131
Rip J, Van Der Ploeg EK, Hendriks RW, Corneth OB. The role of Bruton's tyrosine kinase in immune cell signaling and systemic autoimmunity. Crit Rev Immunol. 2018;38(1):17-62. doi:10.1615/CritRevImmunol.2018025184
Ringheim GE, Wampole M, Oberoi K. Bruton's tyrosine kinase (BTK) inhibitors and autoimmune diseases: making sense of BTK inhibitor specificity profiles and recent clinical trial successes and failures. Front Immunol. 2021;12:662223. doi:10.3389/fimmu.2021.662223
Guo Q, Jin Y, Chen X, et al. NF-κB in biology and targeted therapy: new insights and translational implications. Signal Transduct Target Ther. 2024;9(1):53. doi:10.1038/s41392-024-01757-9
Giuliani C, Bucci I, Napolitano G. The role of the transcription factor nuclear factor-kappa B in thyroid autoimmunity and cancer. Front Endocrinol. 2018;9:471. doi:10.3389/fendo.2018.00471
Barnabei L, Laplantine E, Mbongo W, Rieux-Laucat F, Weil R. NF-κB: at the borders of autoimmunity and inflammation. Front Immunol. 2021;12:716469. doi:10.3389/fimmu.2021.716469
Liu T, Zhang L, Joo D, Sun SC. NF-κB signaling in inflammation. Signal Transduct Target Ther. 2017;2(1):1-9. doi:10.1038/sigtrans.2017.23
Sun SC, Chang JH, Jin J. Regulation of nuclear factor-κB in autoimmunity. Trends Immunol. 2013;34(6):282-289. doi:10.1016/j.it.2013.01.004
Pontoriero M, Fiume G, Vecchio E, et al. Activation of NF-κB in B cell receptor signaling through Bruton's tyrosine kinase-dependent phosphorylation of IκB-α. J Mol Med. 2019;97(5):675-690. doi:10.1007/s00109-019-01777-y
Sharma H, Kakadiya J. Different novel biomarkers involved in diagnosing hypothyroidism. Egypt J Intern Med. 2023;35(1):28. doi:10.1186/s43162-023-00211-2
Pempera N, Miedziaszczyk M, Lacka K. Difficulties in the diagnostics and treatment of Hashimoto's encephalopathy—a systematic and critical review. Int J Mol Sci. 2024;25(13):7101. doi:10.3390/ijms25137101
Tywanek E, Michalak A, Świrska J, Zwolak A. Autoimmunity, new potential biomarkers and the thyroid gland—the perspective of Hashimoto's thyroiditis and its treatment. Int J Mol Sci. 2024;25(9):4703. doi:10.3390/ijms25094703
World Health Organization. Obesity: Preventing and Managing the Global Epidemic. WHO; 2000.
Qiao H, Mao Z, Wang W, et al. Changes in the BTK/NF-κB signaling pathway and related cytokines in different stages of neuromyelitis optica spectrum disorders. Eur J Med Res. 2022;27(1):96. doi:10.1186/s40001-022-00726-y
Liu Y, Zhu Z, Xu Q, et al. Identification of BTK as an immune-related biomarker for Hashimoto's thyroiditis by integrated bioinformatic analysis. BMC Immunol. 2025;26(1):11. doi:10.1186/s12865-025-00683-z
Yardim M, Deniz L, Saltabas MA, Celik N. Effect of thyroxine replacement therapy on serum maresin 1 and NF-kB levels in patients with Hashimoto thyroiditis. Diagnostics. 2025;15(10):1248. doi:10.3390/diagnostics15101248
Li X, Abdel-Mageed AB, Mondal D, Kandil E. The nuclear factor kappa-B signaling pathway as a therapeutic target against thyroid cancers. Thyroid. 2013;23(2):209-218. doi:10.1089/thy.2012.0237
Ghazi SM, Salman AA, Jawad AA. Assessing cardiovascular changes in Iraqi women with hypothyroidism. J Med Life. 2023;16(4):579. doi:10.25122/jml-2023-0060
Petro JB, Rahman SJ, Ballard DW, Khan WN. Bruton's tyrosine kinase is required for activation of IκB kinase and nuclear factor κB in response to B cell receptor engagement. J Exp Med. 2000;191(10):1745-1754. doi:10.1084/jem.191.10.1745
Shinners NP, Carlesso G, Castro I, et al. Bruton's tyrosine kinase mediates NF-κB activation and B cell survival by B cell-activating factor receptor of the TNF-R family. J Immunol. 2007;179(6):3872-3880. doi:10.4049/jimmunol.179.6.3872
Garg N, Padron EJ, Rammohan KW, Goodman CF. Bruton's tyrosine kinase inhibitors: the next frontier of B-cell-targeted therapies for cancer, autoimmune disorders, and multiple sclerosis. J Clin Med. 2022;11(20):6139. doi:10.3390/jcm11206139
Mansour AA, Ali Alhamza AH, Abdullah Almomin AMS, et al. Patterns of thyroid disease in Basrah, Iraq: retrospective study. J Endocr Soc. 2020;4(Suppl 1):SUN-418. doi:10.1210/jendso/bvaa046.1128
Kargar S, Tabatabaei SM, Okati-Aliabad H, Rad HI. Prevalence of thyroid dysfunction disorders among adult populations in the Middle-East: a systematic review and meta-analysis. Open Public Health J. 2024;17(1). doi:10.2174/0118749445282227240115062556
Al-Zamali SKS, Jallod IMS, Mohammed SS, et al. Association between FOXP3 rs2232368 variant and Hashimoto's thyroiditis risk: a case-control study. Cureus. 2025;17(2). doi:10.7759/cureus.75421
Baranowska-Bik A, Bik W. The association of obesity with autoimmune thyroiditis and thyroid function—possible mechanisms of bilateral interaction. Int J Endocrinol. 2020;2020:8894792. doi:10.1155/2020/8894792
Bujnis M, DeSalvo K, Neklason DW, Madsen MJ, Jorde LB. Familial risk of Hashimoto's thyroiditis in a large genealogical database. J Clin Endocrinol Metab. 2025;110(12):e3998-e4003. doi:10.1210/clinem/dgaf023
Tulla S, Azaz S, Khan MSA. Evaluation of BMI in hypothyroid patients and its response to thyroxin therapy. Eur J Cardiovasc Med. 2022;12(4).
Mustafa MD, Tuama RM. The relationship between hypothyroidism and obesity. J Coast Life Med. 2022;10:73-84.
Song Rh, Wang B, Yao Qm, Li Q, Jia X, Zhang Ja. The impact of obesity on thyroid autoimmunity and dysfunction: a systematic review and meta-analysis. Front Immunol. 2019;10:443404. doi:10.3389/fimmu.2019.02349
Huo J, Xu Y, Yu J, et al. Causal association between body mass index and autoimmune thyroiditis: evidence from Mendelian randomization. Eur J Med Res. 2023;28(1):526. doi:10.1186/s40001-023-01520-0
Duntas LH, Biondi B. The interconnections between obesity, thyroid function, and autoimmunity: the multifold role of leptin. Thyroid. 2013;23(6):646-653. doi:10.1089/thy.2012.0524
Abdullah YJ, Essa RH, Jumaa MG. Incidence of Hashimoto's thyroiditis and its relationship to age, sex, smoking and blood groups. NTU J Pure Sci. 2022;1(2):1-9.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2026 European Journal of Clinical and Experimental Medicine

This work is licensed under a Creative Commons Attribution 4.0 International License.
Our open access policy is in accordance with the Budapest Open Access Initiative (BOAI) definition: this means that articles have free availability on the public Internet, permitting any users to read, download, copy, distribute, print, search, or link to the full texts of these articles, crawl them for indexing, pass them as data to software, or use them for any other lawful purpose, without financial, legal, or technical barriers other than those inseparable from having access to the Internet itself.
All articles are published with free open access under the CC-BY Creative Commons attribution license (the current version is CC-BY, version 4.0). If you submit your paper for publication by the Eur J Clin Exp Med, you agree to have the CC-BY license applied to your work. Under this Open Access license, you, as the author, agree that anyone may download and read the paper for free. In addition, the article may be reused and quoted provided that the original published version is cited. This facilitates freedom in re-use and also ensures that Eur J Clin Exp Med content can be mined without barriers for the research needs.




